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Neuroendocrine immunology owes much to the fore-
sighted work of Philip S Hench, who together with 
Edward C Kendall and Tadeus Reichstein introduced 
glucocorticoids (GCs) into clinical medicine. Since the 
1990s, more than 40 years after adding GC to the thera-
peutic armamentarium, important work has been carried 
out to understand GC action. Th ere were three major 
pathways of discoveries between 1990 and today.
Firstly, the groups of George Chrousos and of Steven 
Lamberts deﬁ ned hereditary GC resistance due to abnor-
malities of the GC receptor (ﬁ rst reviewed in [1,2]). 
While genetically determined alterations of the GC 
receptor were rare in the population, inﬂ ammation-
induced local GC receptor resistance became an impor-
tant concept of inﬂ ammation research [3]. Th e concept 
gained momentum, particularly in asthma research. 
Indeed, the local proinﬂ ammatory load negatively inﬂ u-
ences anti-inﬂ ammatory GC action [3], but a workable 
therapeutic approach was not yet introduced into the 
rheumatology hospital.
Secondly, several groups recognized inadequate 
secretion of GC in relation to inﬂ ammation (reviewed by 
Maurizio Cutolo and colleagues in this supplement). 
While an acute inﬂ ammatory trigger can increase GC 
serum levels, this response did not appear after repeated 
administration of the same trigger [4]. Several studies 
demonstrated that proinﬂ ammatory cytokines such as 
interleukin-6, interferon alpha, interferon gamma, and 
others can stimulate the hypothalamic–pituitary–adrenal 
axis, but responses to repeated stimuli were much less 
pronounced. While inadequacy of GC secretion is typical 
for most active inﬂ ammatory diseases, the phenomenon 
can exist for a long time beyond acute inﬂ ammation 
control (that is, imprinting). In such a situation, long-
term therapy with low-dose GC must be recognized as a 
supplementary therapy for the adrenal glands.
Indeed, between 1990 and today the outstanding role 
of low-dose GC (approximately 5 mg/day) was discovered 
in rheumatoid arthritis (RA) patients using placebo-
controlled randomized clinical trials, as summarized in 
this supplement by Marlies van der Goes and colleagues.
In an unstressed individual, the usual daily production of 
endogenous cortisol mounts to 5.7 mg/m2 (depending on 
body surface, ≈10 to 14 mg/day) [5], which equals 2.5 to 
3.5 mg prednisolone/day. Th us, under real-life conditions, 
doses of prednisolone between 2 and 5 mg/day represent 
an adrenocortical substitution therapy. Importantly, low-
dose GC has disease-modifying antirheumatic drug 
eﬀ ects as demonstrated in this supplement.
Th irdly, timing of daily GC administration reached a 
new level of precision with a clear pathophysiological 
concept (reviewed by Cornelia Spies and colleagues). In 
the early days of GC therapy, doctors and patients 
experienced that GC administration in the evening can 
sometimes have beneﬁ cial eﬀ ects the following morning.
However, these positive eﬀ ects were accompanied by 
GC-induced sleep disturbances during the early night. 
Driven by RA patients’ experiences, Arvidson and 
colleagues overcame this problem by administering GC 
at 2:00 a.m., and observed a highly beneﬁ cial eﬀ ect in the 
morning [6]. A more sophisticated method of GC 
administration was developed during the 2000s  – 
modiﬁ ed GC release, which makes use of GC-loaded pills 
taken at bedtime and showing abrupt GC release at 
2:00 a.m. Under these conditions, GC release occurs at a 
time when endogenous inﬂ ammatory pathways are 
switched on in a circadian manner [7]. Th e positive 
eﬀ ects of nightly GC therapy, as demonstrated in RA 
[8,9], are due to immediate inhibition of proinﬂ ammatory 
pathways in the increasing ﬂ ank of nightly inﬂ ammation 
induction [7].© 2010 BioMed Central Ltd
Rheumatoid arthritis – a neuroendocrine immune 
disorder: glucocorticoid resistance, relative 
glucocorticoid defi ciency, low-dose glucocorticoid 




Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, 
Division of Rheumatology, Department of Internal Medicine, University Hospital, 
93042 Regensburg, Germany
Straub Arthritis Research & Therapy 2014, 16(Suppl 2):I1 
http://arthritis-research.com/content/16/S2/I1
© 2014 BioMed Central Ltd
Finally, this supplement presents an article on insulin 
resistance in chronic inﬂ ammatory systemic diseases. 
While it seems, at ﬁ rst glance, that GCs are not related to 
insulin resistance, it turns out that the hypothalamic–
pituitary–adrenal axis and thus endogenous GC play an 
important role in inducing insulin resistance. Please 
recall that GC can induce elevated levels of glucose, free 
fatty acids, and glucogenic amino acids in a physiological 
setting. Insulin resistance is a common phenomenon of 
physiological states, disease states, and diseases. Th is 
resistance typically appears in patients with diabetes 
mellitus, obesity, infection, sepsis, arthritis of diﬀ erent 
types (including RA), systemic lupus erythematosus, 
ankylosing spondylitis, trauma, painful states such as 
postoperative pain and migraine, schizophrenia, major 
depression, and mental stress. By presenting an inte-
grated theory on insulin resistance, Straub puts forward 
the concept that insulin resistance is an evolutionarily 
positively selected program of an activated selﬁ sh brain 
or a stimulated selﬁ sh immune system. Long-term use of 
this adaptive program during chronic activation of the 
brain or the immune system turns out to be a misguided 
program that perpetuates the disease process.
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